These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6981541)

  • 1. [The significance of cellular surface markers in lymphoproliferative disorders].
    Aderka D; Pinkhas J
    Harefuah; 1982 Apr; 102(7):307-10. PubMed ID: 6981541
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetic and immunological considerations on the therapy of immunoproliferative disorders].
    Pileri A; Boccadoro M; Conte P
    Recenti Prog Med; 1979 Feb; 66(2):103-15. PubMed ID: 375339
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.
    Gökçe S; Süoğlu OD; Sökücü S; Gün F; Emiroğlu H; Celik A; Doğan O; Cevikbaş U
    J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):316-20. PubMed ID: 16540802
    [No Abstract]   [Full Text] [Related]  

  • 4. [Correlation between membrane markers and cytochemical markers in acute T-cell lymphoproliferative disorders. Comparison with other acute lymphoproliferative processes].
    Larrocha Rabanal C; Fernández de Castro M; Viloria Vicente A; Jiménez Herráez MC; García Rodríguez MC; Madero Jarabo R
    Sangre (Barc); 1984; 29(4-C):741-51. PubMed ID: 6334899
    [No Abstract]   [Full Text] [Related]  

  • 5. [Double-marker (T + B) lymphocytes in lymphoproliferative diseases].
    Pecze K; Dalmi L; Rák K
    Orv Hetil; 1982 Jun; 123(26):1595-7. PubMed ID: 6981087
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
    Svoboda J; Kotloff R; Tsai DE
    Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spectrum of lymphoproliferative diseases].
    Franssila K
    Duodecim; 1989; 105(11):1016-39. PubMed ID: 2666087
    [No Abstract]   [Full Text] [Related]  

  • 8. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
    Mazza P; Palazzo G; Amurri B; Pricolo G; Prudenzano A; Stani L
    Haematologica; 2001 Oct; 86(10):1104-5. PubMed ID: 11602420
    [No Abstract]   [Full Text] [Related]  

  • 9. [Some immunological aspects of lymphoproliferative syndromes (author's transl)].
    Ruíz-Argüelles J; Díaz-Jouanen E
    Rev Invest Clin; 1979; 31(2):181-92. PubMed ID: 314145
    [No Abstract]   [Full Text] [Related]  

  • 10. Biologic and clinical heterogeneity of lymphoproliferative diseases of peripheral mature T lymphocytes.
    Pandolfi F; Zambello R; Cafaro A; Semenzato G
    Lab Invest; 1992 Sep; 67(3):274-302. PubMed ID: 1405488
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunologic cell markers in lymphoproliferative diseases].
    Samoĭlova RS
    Ter Arkh; 1980; 52(9):140-9. PubMed ID: 7001662
    [No Abstract]   [Full Text] [Related]  

  • 12. Flow cytometric assessment of T-cell chronic lymphoproliferative disorders.
    Cady FM; Morice WG
    Clin Lab Med; 2007 Sep; 27(3):513-32, vi. PubMed ID: 17658405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cell morphology and surface markers in three patients with granular lymphocyte proliferative disorders of the T-cell type].
    Mishima M; Harada K; Kozono T; Maruyama I
    Rinsho Byori; 1994 Jan; 42(1):94-9. PubMed ID: 8107290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Heterogeneity of T gamma-lymphoproliferative disorder-- case report and review of the literature].
    Hara J; Kawa-ha K; Doi S; Yumura K; Ishihara S; Kurahashi H; Yabuuchi H
    Rinsho Ketsueki; 1986 Dec; 27(12):2325-32. PubMed ID: 3553644
    [No Abstract]   [Full Text] [Related]  

  • 15. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
    Saven A; Piro LD
    Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristic expansion of CD45RA CD27 CD28 CCR7 lymphocytes with stable natural killer (NK) receptor expression in NK- and T-cell type lymphoproliferative disease of granular lymphocytes.
    Mitsui T; Maekawa I; Yamane A; Ishikawa T; Koiso H; Yokohama A; Handa H; Matsushima T; Tsukamoto N; Murakami H; Nojima Y; Karasawa M
    Br J Haematol; 2004 Jul; 126(1):55-62. PubMed ID: 15198732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of investigative diagnostic techniques for cutaneous lymphoma.
    Slater DN
    Semin Dermatol; 1994 Sep; 13(3):166-71. PubMed ID: 7986684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
    Meng HT; Li Y; Liu JH; Xu GX; Teng XD
    Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
    [No Abstract]   [Full Text] [Related]  

  • 19. [Regulation of growth and development of T-lymphocyte colonies from normal subjects and in lymphoproliferative disorders].
    Shoham D; Goldman J; Radnay J; Gotthelf Y; Katzevman E; Joseph D; Werber MM; Rozenszajn LA
    Harefuah; 1982 Sep; 103(5-6):81-7. PubMed ID: 6984839
    [No Abstract]   [Full Text] [Related]  

  • 20. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Pawelski S
    Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.